Back to Search
Start Over
Protective effect of cilastatin against diclofenac‐induced nephrotoxicity through interaction with diclofenac acyl glucuronide via organic anion transporters
- Source :
- Br J Pharmacol
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- Background and purpose Diclofenac is a widely used nonsteroidal anti-inflammatory drug. However, adverse effects in the kidney limit its clinical application. The present study was aimed to evaluate the potential effect of cilastatin on diclofenac-induced acute kidney injury and to clarify the potential roles of renal organic anion transporters (OATs) in the drug-drug interaction between cilastatin and diclofenac. Experimental approach The effect of cilastatin was evaluated in diclofenac-induced acute kidney injury in mice. Human OAT1/3-transfected HEK293 cells and renal primary proximal tubule cells (RPTCs) were used to investigate OAT1/3-mediated transport and the cytotoxicity of diclofenac. Key results Cilastatin treatment decreased the pathological changes, renal dysfunction and elevated renal levels of oxidation products, cytokine production and apoptosis induced by diclofenac in mice. Moreover, cilastatin increased the plasma concentration and decreased the renal distribution of diclofenac and its glucuronide metabolite, diclofenac acyl glucuronide (DLF-AG). Similarly, cilastatin inhibited cytotoxicity and mitochondrial damage in RPTCs but did not change the intracellular accumulation of diclofenac. DLF-AG but not diclofenac exhibited OAT-dependent cytotoxicity and was identified as an OAT1/3 substrate. Cilastatin inhibited the intracellular accumulation and decreased the cytotoxicity of DLF-AG in RPTCs. Conclusion and implications Cilastatin alleviated diclofenac-induced acute kidney injury in mice by restoring the redox balance, suppressing inflammation, and reducing apoptosis. Cilastatin inhibited OATs and decreased the renal distribution of diclofenac and DLF-AG, which further ameliorated the diclofenac-induced nephrotoxicity in mice. Cilastatin can be potentially used in the clinic as a therapeutic agent to alleviate the adverse renal reaction to diclofenac.
- Subjects :
- 0301 basic medicine
Diclofenac
Organic anion transporter 1
Metabolite
Organic Anion Transporters
Organic Anion Transporters, Sodium-Independent
Pharmacology
Kidney
Nephrotoxicity
Mice
03 medical and health sciences
chemistry.chemical_compound
Glucuronides
0302 clinical medicine
polycyclic compounds
medicine
Animals
Humans
Cilastatin
biology
Acute kidney injury
medicine.disease
Research Papers
stomatognathic diseases
HEK293 Cells
030104 developmental biology
medicine.anatomical_structure
chemistry
biology.protein
lipids (amino acids, peptides, and proteins)
Glucuronide
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- ISSN :
- 14765381 and 00071188
- Volume :
- 177
- Database :
- OpenAIRE
- Journal :
- British Journal of Pharmacology
- Accession number :
- edsair.doi.dedup.....edfb67c426247f8b96356a6995819b86
- Full Text :
- https://doi.org/10.1111/bph.14957